A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Pfizer
National Cancer Institute (NCI)
Pfizer
AstraZeneca
BioNTech SE
Boehringer Ingelheim
DualityBio Inc.
AbbVie
Hansoh BioMedical R&D Company
Eli Lilly and Company
Shandong Suncadia Medicine Co., Ltd.
Lomond Therapeutics Holdings, Inc.
DualityBio Inc.
GRIN Therapeutics, Inc.
AstraZeneca
Kura Oncology, Inc.
VA Office of Research and Development
University of Kansas Medical Center
Amgen
Celgene
Jiangsu HengRui Medicine Co., Ltd.
Ipsen
Jiangsu vcare pharmaceutical technology co., LTD
Nuvation Bio Inc.
BeiGene
Astellas Pharma Inc
University of Chicago
Bayer
AstraZeneca
Jemincare
Hutchmed
Indiana University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Daiichi Sankyo
Boehringer Ingelheim
Hutchmed
Pfizer
Hospital Universitario Dr. Jose E. Gonzalez
AstraZeneca
Tanta University
AstraZeneca
Dallas VA Medical Center
Dallas VA Medical Center
University of Ulm
Impact Therapeutics, Inc.
Odonate Therapeutics, Inc.
Pfizer
University of Texas Southwestern Medical Center
AstraZeneca
University Health Network, Toronto